Replies to post #191743 on Biotech Values

[ghmm]

PPV's:

Its interesting how much these have gone for. When BMRN got theirs I had no idea what type of value to place on them and when they sold it (I think 60-70m) I thought it was a good price obviously not by the later deals.

I think these tend to be of greatest value to two groups the sellers if they are small biotech to raise cash without diluting and to the buyers (though there is a large market then I thought). For BMRN it really didn't appear to be of much value since most of their pipeline will get priority review anyway. Similarly UTHR said they did not see 100-200M of much value for them what they hope to do is be able to trade it to get rights to a compound (they mentioned specifically perhaps getting an approved compound but pediatric use).